Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, June 30, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2025 (2025-06-30): -508.27%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-408.40%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Medicus Pharma Ltd. Common Stock
Market Cap
$10.10M
Return on Equity (ROE)
N/A
TTM Avg
-408.40%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.18M
Return on Equity (ROE)
-310.94%
TTM Avg
727.99%
3Y Avg
459.17%
5Y Avg
300.20%
Market Cap
$9.98M
Return on Equity (ROE)
-157.76%
TTM Avg
-137.97%
3Y Avg
-196.09%
5Y Avg
-89.86%
Market Cap
$9.97M
Return on Equity (ROE)
N/A
TTM Avg
-652.54%
3Y Avg
-364.25%
5Y Avg
-252.47%
Market Cap
$9.92M
Return on Equity (ROE)
-57.34%
TTM Avg
-65.47%
3Y Avg
-124.96%
5Y Avg
28.05%
Market Cap
$9.79M
Return on Equity (ROE)
-440.15%
TTM Avg
-145.56%
3Y Avg
-96.97%
5Y Avg
-42.16%
Market Cap
$11.13M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$10.52M
Return on Equity (ROE)
N/A
TTM Avg
-22.56%
3Y Avg
-244.57%
5Y Avg
3710.91%
Market Cap
$9.66M
Return on Equity (ROE)
-189.76%
TTM Avg
-774.75%
3Y Avg
-460.85%
5Y Avg
-442.56%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medicus Pharma Ltd. Common Stock (MDCX) | $10.10M | N/A | -408.40% | N/A | N/A |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.18M | -310.94% | 727.99% | 459.17% | 300.20% |
| Valion Bio, Inc. (VBIO)vs › | $9.98M | -157.76% | -137.97% | -196.09% | -89.86% |
| Senti Biosciences, Inc. (SNTI)vs › | $9.97M | N/A | -652.54% | -364.25% | -252.47% |
| Satellos Bioscience Inc. (MSLE)vs › | $9.92M | -57.34% | -65.47% | -124.96% | 28.05% |
| Ainos, Inc. (AIMD)vs › | $9.79M | -440.15% | -145.56% | -96.97% | -42.16% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.13M | N/A | -43.97% | -160.70% | -188.29% |
| Polyrizon Ltd. (PLRZ)vs › | $10.52M | N/A | -22.56% | -244.57% | 3710.91% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.66M | -189.76% | -774.75% | -460.85% | -442.56% |
| MetaVia Inc. (MTVA)vs › | $9.62M | -211.76% | -295.58% | -182.53% | -207.81% |
ROE
N/A
ROA
-204.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -508.27% |
| 2025-03-31 | -673.62% |
| 2024-12-31 | -355.87% |
| 2024-09-30 | -327.11% |
| 2024-06-30 | -177.14% |
